Another GLP-1/GIP/glucagon receptor triagonist known as retatrutide (previously LY3437943) was developed by Eli Lilly in 2022 leading to weight loss, reduced fat mass, decreased blood glucose and insulin levels in obese mice, which was attributed to increased energy expenditure and lipid oxidation [62]
Entre ellos se encuentran semaglutida (Ozempic para diabetes, Wegovy para control de peso), liraglutida (Victoza para diabetes, Saxenda para control de peso), dulaglutida (Trulicity, solo para diabetes) y tirzepatida (Mounjaro para diabetes, Zepbound para control de peso), siendo esta ltima un agonista dual que acta sobre los receptores GIP y GLP-1
Convenient capsules easy to take and gentle on the stomach
We understand that losing weight involves more than numbers on a scale
Sweating, shakiness, hunger, irritability, confusion